Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 42Urinary Bladder Neoplasms 18Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 11Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Breast Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Fallopian Tube Neoplasms 9Lung Neoplasms 8Carcinoma, Transitional Cell 8Biliary Tract Neoplasms 7Recurrence 6Gallbladder Neoplasms 6Neoplasms 5Cholangiocarcinoma 5Non-Muscle Invasive Bladder Neoplasms 4Colorectal Neoplasms 4Urothelial Cancer 3Stomach Neoplasms 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Carcinoma 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Adenocarcinoma 2Non Small Cell Lung Carcinoma NSCLC 2

Interventions

pembrolizumab 1Taxes 1Paclitaxel 1Nivolumab 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma, Clear Cell × Gemcitabine × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡